Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

Status Completed

Clinical Trial Summary

Phase 1, open-label, non-randomized, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HBI-8000 administered orally.

Clinical Trial Description

Phase 1, open-label, non-randomized, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HBI-8000 administered orally. Patients must be hospitalized as per guidance of the treating investigator throughout Cycle 1. Patients will receive HBI 8000 twice weekly (BIW) (after breakfast), in 28 day treatment cycles.

Patients will be enrolled in cohorts of 3 patients. The first cohort of 3 patients will receive 30 mg BIW. Decisions regarding cohort escalation will be based upon the clinical experience in Cycle 1 (first 28 days) only. For a given cohort, if 1 patient enrolled in the cohort experiences a dose limiting toxicity (DLT) within 28 days of the first dose, the cohort will be expanded to 6 patients. ;

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02697552
Study type	Interventional
Source	HUYA Bioscience International
Contact
Status	Completed
Phase	Phase 1
Start date	March 2014
Completion date	October 2016

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03844048` - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial	Phase 3
Completed	`NCT01878890` - Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.	Phase 1
Completed	`NCT04152148` - A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients	Phase 1
Recruiting	`NCT05096234` - 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma	Phase 2
Recruiting	`NCT05191225` - Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study	Phase 4
Recruiting	`NCT05623982` - Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03664635` - MB-CART20.1 Lymphoma	Phase 1/Phase 2
Recruiting	`NCT02356159` - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation	Phase 1/Phase 2
Terminated	`NCT01699581` - Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant	Phase 2
Completed	`NCT01763398` - Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study	N/A
Completed	`NCT01205503` - Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release	Phase 2
Completed	`NCT00969462` - Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma	Phase 4
Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
Completed	`NCT00659425` - CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma	Phase 1
Completed	`NCT00608907` - An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)	Phase 1
Withdrawn	`NCT00577161` - Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL	Phase 3
Terminated	`NCT00475332` - Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar	Phase 2
Completed	`NCT00533728` - Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma	Phase 1
Completed	`NCT00430352` - MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.	Phase 4
Completed	`NCT00581646` - Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance	N/A